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What is already known about this subject 
 Despite the clear relationship between BMI and the comorbidities associated with excess body fatness, 
the use of BMI is not without its limitations since by its very definition, BMI cannot distinguish 
between fat and fat-free mass 
 The presence of fasting hypertriglyceridemia alongside abdominal obesity may provide a useful 
indicator of visceral adiposity 
 The hypertriglyceridemic waist phenotype is a simple and inexpensive screening tool to identify adults 
at increased risk of cardiovascular disease and diabetes. 
 
What this study adds 
 The HTWP may confer an improved discriminatory power when compared to WC and BMI for 
identifying individuals with elevated cardiometabolic risk profiles.  
 The measurement of the hypertriglyceridemic waist phenotype appears to distinguish high risk 
viscerally obese individuals of the same weight status who may be more susceptible to related 
metabolic complications. 
 The addition of fasting triglycerides to waist circumference in order to identify the 
hypertriglyceridemic waist phenotype is a convenient and cost-effective means to identify those at 






















Background: It is unclear whether the Hypertriglyceridemic Waist Phenotype can be used to identify those at 
most risk of cardiometabolic disorders. 
Objectives: The utility of the Hypertriglyceridemic Waist Phenotype (HTWP) as a useful predictor of 
cardiometabolic risk in youth stratified by body mass index (BMI) was assessed.  
Methods: Three hundred and eighty seven children (12-17.5 years) were used within this cross-sectional study. 
Participants were classified as normal weight or overweight/obese according to the IOTF criteria. The HTWP 
phenotype was defined as having a waist circumference ≥ 90th percentile for age and gender with concomitant 
triglyceride concentrations ≥ 1.24 mmol/L. Cardiometabolic risk profiles were compared using MANCOVA.  
Results: Normal weight participants with the HTWP had significantly higher levels of C-reactive protein 2.6 ± 
0.4 vs. 1.6 ± 0.3 mg/L (P < 0.05) and cardiometabolic risk scores (1.3 ± 0.3 vs. -0.7 ± 0.2 and 2.1 ± 0.4 vs. -0.5 
± 0.2; both P <  0.05) compared to those of a normal weight without the HTWP. Overweight/obese participants 
with the HTWP had significantly higher C-reactive protein levels (3.5 ± 0.6 vs. 2.6 ± 0.5; P < 0.05) as well as 
both cardiometabolic risk scores (1.6 ± 0.6 vs. 0.9 ± 0.2 and 2.2 ± 0.6 vs. 0.8 ± 0.2; both P < 0.001) when 
compared to overweight/obese participants without the HTWP.   
Conclusions:  













Despite the clear relationship between body mass index (BMI) and the comorbidities associated with excess 
body fatness, the use of BMI is not without its limitations since by its very definition, it cannot distinguish 
between fat and fat-free mass (1). Excessive abdominal obesity is regularly cited as a key mediator of 
cardiometabolic dysfunction given its association with cardiometabolic risk and mortality (2) . The 
measurement of waist circumference (WC) is often used as a simple and inexpensive proxy measure of 
abdominal obesity but despite its widespread use, it is unable to distinguish between subcutaneous and the more 
pathogenic, visceral adiposity (2). Recently, the hypertriglyceridemic waist phenotype (HTWP) (elevated waist 
circumference and elevated triglyceride concentrations) has been proposed as a cost-effective and potentially 
useful proxy measure of visceral adiposity to identify at-risk individuals likely to benefit from lifestyle 
intervention (2-5). 
From the available evidence that has examined the presence and clinical utility of HTWP to identify 
cardiometabolic risk in youth (3-7) some limitations exist. For instance, in an already limited sample size, it is 
unclear how many participants had both pre and post metabolic samples in the subsequent analysis performed 
by Hobkirk and colleagues (4) whereas the absence of measures of low-grade systemic inflammation (3, 6) and 
cardiorespiratory fitness (5, 6), both associated with cardiometabolic risk (8, 9), may have underrepresented the 
magnitude of risk. Finally, in these previous studies (3-7) the authors were interested in estimating the 
prevalence of the metabolic syndrome or the HTWP rather than examining the clinical utility of the HTWP to 
further identify cardiometabolic risk in participants stratified by obesity. Thus, the aim of this cross-sectional 
study was to examine the clinical utility of the HTWP to differentiate the cardiometabolic risk of youth already 
stratified by BMI. It was hypothesized that in the presence of the HTWP, participants would exhibit a greater 
risk profile than those without the HTWP regardless of weight status.  
Materials and Methods 
Data was derived from studies evaluating the health status of Scottish and Welsh youth. Study methodologies 
have been described previously (10, 11). Each study was approved by the University of the West of Scotland 
and the University of South Wales institutional research ethics committees, prior to the recruitment of 467 
children aged 12-17.5 years. After excluding those participants who were absent from data collection, 
withdrawal of blood sampling consent or having identified themselves as being non-fasted, 387 children aged 




Stature was measured to the nearest 1 mm using a portable stadiometer (Seca Stadiometer, Seca Ltd, 
Birmingham, UK and Holtain Ltd, Crymych, Pembrokeshire, UK). Mass without shoes, was measured to the 
nearest 0.1 kg using calibrated electronic weighing scales (Seca 880, Digital Scales, Seca Ltd, Birmingham, UK 
or Holtain Ltd, Crymych, Pembrokeshire, UK ).WC was measured at the narrowest point between the lower ribs 
and iliac crest (natural waist) using an anthropometric tape in accordance with established guidelines (12). 
Systolic and diastolic BP (mmHg) was determined using automated monitors (Omron M10-IT Blood Pressure 
Monitor HEM-7080IT-E, Omron Healthcare UK Ltd, Milton Keynes, UK and a Dinamap XL automatic BP 
monitor, Critikron, Inc., Tampa, FL) after participants had sat quietly for a minimum of 5 minutes. The average 
of the second and third measures was used as the criterion value. Cardiorespiratory fitness (CRF) was measured 
using the 20m multi stage fitness test as described previously (13). Free school meal eligibility was used as a 
measure of socio-economic status (SES). The lead researcher of each study captured all WC measurements at 
each location. Intraclass correlations between the two researchers demonstrated almost perfect reliability (data 
not shown).   
Blood Biochemistry 
Venous blood was sampled following an overnight fast and 30 min seated rest. Blood was sampled from the 
antecubital vein and collected in a BD Vacutainer plasma tube (Becton, Dickinson and Company, Franklin 
Lakes, USA). Plasma was isolated by centrifugation at 3,500 rpm for 10 minutes, transferred to aliquots and 
frozen at -80oC within two hours of collection. Samples were subsequently analysed for insulin, high density 
lipoprotein cholesterol (HDL-c), total cholesterol (TC), C-reactive protein (CRP), glucose and triglycerides 
(TG). Metabolic measurements were taken on a separate day to all other measurements. The homeostatic model 
assessment of insulin resistance (HOMA) calculation was used as an indication of insulin resistance calculated 
as the product of fasting glucose (mmol/L) and insulin (𝜇U/mL) divided by the constant 22.5 (14).  
Cardiometabolic risk 
Cardiometabolic risk scores for each participant were constructed using the following four variables: Systolic 
BP, TC:HDL-c ratio, HOMA-IR and CRP. These variables were selected based on the guidance provided 
through two recent scientific statements (15, 16).  Traditional risk factors such as Systolic BP, TC:HDL-c ratio 
and measures of IR are strongly associated with atherosclerotic vascular disease in early adulthood (15) but the 
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progression of atherosclerosis from childhood fatty streaks to clinically significant fibrous plaques during young 
adulthood is also well-established (17). Thus, establishing associations between simple and inexpensive 
screening tools with individuals presenting with elevated levels of these risk factors may assist in the early 
identification of at risk individuals. The inclusion of the biomarker CRP was included within the  risk score 
since evidence suggests that inflammation is central to all stages of atherosclerosis with CRP being one of the 
most sensitive indicators (16, 18). Whilst evidence in youth does not suggest that CRP is predictive or casual to 
a disease outcome, its inclusion may identify those with increased risk profiles (16, 18).   
A second cardiometabolic risk score was also constructed that included the z-score of cardiorespiratory fitness 
(inverted). CRF is known to be independently and inversely associated with cardiometabolic risk in youth (9, 
11, 19) thus its inclusion within a cardiometabolic risk score may assist with the identification of those in most 
need of lifestyle modification. Each variable was standardized as follows: standardized value = value-mean/SD, 
separately for boys and girls and by 1 yr. age groups. Individual z-scores were subsequently summed with a 
lower score being indicative of a healthier profile. Prior to the construction of the cardiometabolic risk scores, 
HOMA-IR, TC:HDL-c and CRP were normalised by log transformation (back transformed throughout for 
presentation purposes).  
HTWP and Weight Status Groups 
The HTWP was defined according to thresholds previously applied (3). Reference values from the National 
Cholesterol Education Program’s (NCEP) Pediatric Panel Report (20) define a borderline high range for 
triglycerides as 90-129 mg/dL (1.02-1.46 mmol/L). Thus, 1.24 mmol/L was used as the midpoint value and was 
taken as the 90th percentile value for age. In participants < 17 years, a high WC was defined as ≥ 90th percentile 
for age and sex as previously described (22). For participants aged ≥ 17 years, high WC in males and females 
was defined as ≥ 94 and 80 cm (21). BMI was calculated and used to classify participants as obese/overweight, 
or a healthy weight using recommended international age and gender-specific values (23).  
Statistical Analysis 
Data was analysed using SPSS V20.0 (SPSS Statistics, IBM Corp.), with values of P < 0.05 considered 
statistically significant. Data was checked for normality of distribution before analyses. As no significant 
interaction was found for age, sex, SES or study location  all analyses were performed with boys and girls 
together. Differences in the mean values (mean ± standard error and 95% CIs) of the cardiometabolic risk scores 
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and individual risk factors between groups and within sub-groups (normal weight and overweight/obese as well 
as HTWP and non HTWP) were conducted using MANCOVA controlling for age, gender, SES and study 
location. Bonferroni’s adjustments for multiple comparisons were used to examine contrasts across groups. 
Multivariate logistic regression was used to determine the likelihood (OR, 95%CI) of having adverse levels of 
the following indicators of cardiometabolic risk: TC:HDL-c, HOMA, Systolic BP, CRF, CRP, cardiometabolic 
risk score (excluding CRF) and cardiometabolic risk score (including CRF). All regression models were 
controlled for age, sex, SES and study location. Three separate multivariate logistic regression models were 
used taking the absence or presence of elevated WC, BMI and HTWP (yes/no) as the dependant variable. 
Adverse levels were defined as the age and sex specific top tertile of each cardiometabolic risk indicator (except 
for CRF) with the lower two tertiles used as the reference group: bottom tertile versus the rest for CRF. Finally, 
the discriminant function analysis tool was used to determine which variables discriminate individuals likely to 
present with HTWP based on weight status. The resulting classification matrices provided evidence of the 
relative importance of each predictor in distinguishing groups.  
Results 
Table 1 illustrates the prevalence of normal weight, overweight/obese and HTWP groups.  The prevalence of 
overweight and obese participants was 36.2% (n = 140) and 5.5% (n = 21). Given the low prevalence of obese 
participants, the obese and overweight participants were analysed together. Participants in the overweight/obese 
group demonstrated significantly higher adjusted mean levels of mass, BMI, WC, systolic and diastolic BP, 
HOMA-IR, TC:HDL-c and CRP in addition to significantly lower CRF levels. The overweight/obese group also 
had significantly greater mean adjusted values for both cardiometabolic risk scores compared with the normal 
weight group. Similar findings were also evident between the HTWP and non-HTWP groups. Participants in the 
HTWP group displayed significantly higher adjusted mean levels of mass, BMI and TC:HDL-c in addition to 
significantly lower CRF levels. Both cardiometabolic risk scores were also significantly higher within the 
HTWP group. 
Multivariate adjusted OR’s (and 95% CI’s) for adverse levels of cardiometabolic risk indicators across HTWP, 
BMI and WC categories are presented in Supplementary Table 1 (available online). Participants with the HTWP 
were significantly more likely to have elevated Systolic and Diastolic BP, CRP and cardiometabolic risk scores 
as well as lower CRF levels compared to those without the HTWP. Overweight/obese individuals were 
significantly more likely to have lower CRF levels than those of a healthy weight. Finally, those with a high WC 
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were significantly more likely to have elevated CRP and cardiometabolic risk scores compared to those of a 
healthy WC.  
To illustrate the clinical utility of the HTWP, differences in the mean values of the cardiometabolic risk scores 
and individual indicators of risk between groups and within sub-groups were examined (Tables 2 and 3) using 
MANCOVA controlling for age, gender, SES and study location. Participants presenting with the HTWP were 
further divided into two sub-groups based on their weight status (Table 2). Participants with the HTWP who 
were overweight/obese had significantly greater mean adjusted values for mass, BMI and WC only when 
compared to those of a normal weight presenting with the HTWP. Comparisons between participants who were 
of a normal weight or overweight/obese with or without the HTWP are provided in Table 3. Participants of a 
normal weight but with the HTWP displayed significantly higher adjusted mean levels of TC:HDL-c ratio (3.2 ± 
0.2 vs. 2.6 ± 0.1; 95% CI for difference 1.2 to 0.4, P <0.001), CRP (2.6 ± 0.4 vs. 1.6 ± 0.3 mg/L; 2.1 to -0.7, P < 
0.05) and both cardiometabolic risk scores (1.3 ± 0.3 vs. -0.7 ± 0.2; 2.2 to 0.6 (excluding CRF) and 2.1 ± 0.4 vs. 
-0.5 ± 0.2; 2.2 to 0.5 (including CRF), both P <  0.05) compared to normal weight participants without the 
HTWP. Similar results were evident for those within the overweight/obese group with participants presenting 
with the HTWP demonstrating significantly greater mean adjusted values for CRP (3.5 ± 0.6 vs. 2.6 ± 0.5 mg/L; 
3.3 to -1.7, P < 0.05) and both cardiometabolic risk scores (1.6 ± 0.6 vs. 0.9 ± 0.2; 2.2 to -0.2, (excluding CRF),  
and 2.2 ± 0.6 vs. 0.8 ± 0.2; 2.8 to 0.2 (including CRF), both P < 0.001). 
Finally, findings from the discriminant analysis are provided in Supplementary Table 2 (available online). For 
healthy weight individuals (in relation to BMI) with the HTWP, variables accounted for 41.9% of between 
group variability with cardiometabolic risk (including CRF) (-0.759) contributing to the maximum separation 
between groups. For overweight/obese individuals with the HTWP, variables accounted for 29.6% of between 
group variability with cardiometabolic risk (including CRF) (-0.745) contributing to the maximum separation 
between groups.  
Discussion  
In this cross-sectional study we used the HTWP as a proxy measure of visceral adiposity to examine the 
cardiometabolic risk profiles in groups of normal weight and overweight/obese youth stratified by BMI. Near 
identical findings were evident when comparisons were made between those with and without the HTWP (Table 
1) and confirms the findings of others suggesting that the HTWP may serve as a useful diagnostic tool (3-5). 
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Findings from Supplementary Table 1 suggest that the HTWP may confer an improved discriminatory power 
when compared to WC and BMI for identifying individuals with elevated cardiometabolic risk profiles. Whilst 
direct comparison between studies is difficult, these findings appear in agreement with some (3, 5) although 
others suggest that BMI demonstrates a similar ability in distinguishing youth with and without elevated 
cardiometabolic risk when compared to WC and waist-height ratio (24, 25).   
We found minimal differences, other than those expected, in indicators of cardiometabolic risk between 
individuals with the HTWP stratified by BMI (Table 2). Of particular interest are the findings from Table 3. We 
found that normal weight individuals with the HTWP had significantly higher TC:HDL-c and CRP levels as 
well as cardiometabolic risk scores in comparison to those without. Similarly, overweight/obese individuals 
with the HTWP had significantly higher levels of CRP and greater cardiometabolic risk scores than participants 
of a same weight but without the HTWP. To the best of our knowledge this is the first study that has used the 
HTWP to examine the CRP levels in youth of the same weight status, and may provide an explanation for the 
differences in cardiometabolic risk scores evident between the sub-groups in Table 3.  
One could argue from our data that BMI alone has the predictive ability to identify individuals in most need of 
lifestyle modification. We don’t disagree that BMI has clearly established the link between obesity and the 
likelihood of health related disorders (26, 27) but not every obese individual will develop these complications 
(28). It is telling that there are limited meaningful differences in cardiometabolic risk evident in the subgroups 
from table 2 but from table 3, the measurement of this phenotype appears to distinguish high risk viscerally 
obese individuals of the same weight status who may be more susceptible to related metabolic complications. 
Nonetheless, an inherent weakness within our study design is the lack of any outcome data. 
Despite this, we are able to draw upon the limited available evidence in youth which highlights the importance 
of identifying these phenotypes early. Li and colleagues examined the cardiometabolic risk profile of individuals 
who participated in the Bogalusa Heart Study between 1973 and 2002 (29). The authors demonstrated that 
metabolically healthy but obese children had favourable cardiometabolic risk profiles as adults in comparison to 
those classified as metabolically abnormal overweight/obese children. Furthermore, despite significantly 
increased obesity in adulthood, those identified as  metabolically healthy but obese as children  had comparable 
cardiometabolic risk profiles as adults to those who were metabolically healthy, and non-overweight/obese as 
children (29). Such important observations suggest that relying upon BMI alone to stratify those at risk may be a 
poor method of identifying those in need of lifestyle modification.  
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Findings of this study and previous investigations (3-5) suggest that the HTWP is a convenient method which 
may serve as an effective tool for initial screening. Since measurements of WC and fasting triglycerides are 
inexpensive and readily available within a clinical setting, further prolonged prospective study is encouraged to 
determine whether the measurement of this phenotype could improve the ability of practitioners to identify at 
risk individuals. 
There are important limitations that should be noted. Chronological age was used as a proxy for maturation 
within our analysis. Since adiposity distribution and metabolic indicators of cardiometabolic disease are 
influenced by pubertal status, future work should ensure that pubertal status is controlled for particularly when 
comparing between sexes. Another limitation of this study was the lack of objectively measured physical 
activity and dietary habits which are well-established confounders of a number of indicators measured. We 
acknowledge the limitations of HOMA-IR compared with the gold standard, the Hyperinsulinemic-euglycemic 
clamp technique. However, due to convenience and cost-saving, HOMA-IR is often used as a surrogate measure 
of IR in cross-sectional studies. Furthermore, whilst the use of clustered cardiometabolic risk scores is common 
within paediatric research it does have its limitations. The z-score approach is based on the premise that each 
selected variable is equally important in defining cardiometabolic risk, but at present, this has not been 
confirmed. Nonetheless, the use of a composite risk score may compensate to some extent the day-to-day 
fluctuation in single risk indicators. The inclusion of CRF within the composite risk score is an additional 
strength of this study as is the inclusion of C-reactive protein both of which appear to be significant 
determinants of group membership, as well as contributing as part of the cardiometabolic risk score to the 
maximum separation between groups (Supplementary Table 2). 
In summary, the addition of fasting triglycerides to WC to identify the HTWP appears to be a convenient and 
cost-effective means to identify those at increased cardiometabolic risk regardless of weight status. Nonetheless, 
further work is warranted to verify our findings and examine the utility of HTWP to distinguish cardiometabolic 
risk across differing age ranges, ethnic groups and subsequently identify optimal threshold values. 
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 Table 1 – Comparison of anthropometric, body composition and cardiometabolic risk variables based on weight status and the HTWP. 
 
Values are presented as mean ± (SE). BMI = Body mass index; HOMA-IR = homeostasis model assessment for Insulin Resistance; TC: HDL-c Ratio = Total 
cholesterol to high-density lipoprotein cholesterol ratio.  
* Cardiometabolic risk score excluding cardiorespiratory fitness 




Variable Normal Weight (n 
= 226) 
Overweight / 
Obese (n = 161) 
95% CI for 
difference 
P value Non HTWP (n = 304) HTWP (n = 83) 95% CI for 
difference 
P value 
Age (yrs) 13.8 ± 0.1 14.2 ± 0.2 -0.8 to 0.1 0.066 13.6 ± 0.1 13.8 ± 0.3 -0.7 to 3.4 0.523 
Height (cm) 160 ± 0.7 161 ± 0.7 -2.8 to 1.1 0.393 160.5 ± 0.6 160.7 ± 1.1 -2.7 to 2.3 0.882 
Mass (kg) 50.2 ± 0.7 66.3 ± 0.7 -18.1 to -14.1 <0.001 54.0 ± 1.6  58.5 ± 0.8 -8.1 to -0.8 0.017 
BMI 19.3 ± 0.2 25.4 ± 0.2 -6.7 to -5.6 <0.001 22.4 ± 0.3 20.8 ± 0.5 0.4 to 2.8 0.008 
Systolic BP (mm Hg) 116 ± 1 120 ± 1 -6.4 to -0.6 0.019 117 ± 1 119 ± 2 -5.0 to 2.7 0.576 
Diastolic BP (mm Hg) 67.2 ± 0.9  71.1 ± 0.9 -6.5 to -1.3 0.003 70 ± 1 68 ± 1 -1.5 to 5.4 0.272 
HOMA-IR 1.4 ± 0.1 1.1 ± 0.1 -0.5 to -0.1 0.064 1.5 ± 0.1 1.7 ± 0.1 -0.5 to 0.1 0.294 
TC:HDL-c Ratio 2.9 ± 0.1 3.3 ± 0.1 -0.8 to -0.2 <0.001 3.0 ± 0.1 3.5 ± 0.2 -0.8 to -0.1 0.006 
C-reactive protein  
(mg/L) 
1.8 ± 0.3 2.7 ± 0.4 -1.8 to 0.1 0.055 2.1 ± 0.3 2.6 ± 0.5 -1.7 to 0.8 0.438 
Cardiorespiratory 
fitness (shuttles) 
63.5 ± 1.4 53.2 ± 1.6 6.1 to 14.6 <0.001 62.4 ± 2.5 54.9 ± 1.3 -10.2 to 1.4 0.002 
Cardiometabolic risk* -0.2 ± 0.1 1.1 ± 0.2 -1.9 to -0.9 <0.001 0.1 ± 0.2 1.1 ± 0.3 -1.7 to -0.3 0.006 
Cardiometabolic risk** 0.1 ± 0.2 1.1 ± 0.2 -1.5 to -0.4 <0.001 0.2 ± 0.2 1.3 ± 0.3 -1.8 to -0.4 0.002 
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Table 2 – Comparison of anthropometric, body composition and cardiometabolic risk variables between normal weight and obese/overweight participants 











Values are presented as mean ± (SE). BMI = Body mass index; HOMA-IR = homeostasis model assessment for Insulin Resistance; TC:HDL-c Ratio = Total 
cholesterol to high-density lipoprotein cholesterol ratio. 
* Cardiometabolic risk score excluding cardiorespiratory fitness 




Variable Normal Weight 
(n = 55) 
Overweight / 
Obese (n = 28) 
95% CI for 
difference 
P value 
Age (yrs) 13.0 ± 0.1 13.2 ±  0.1 -0.4 to 0.1 0.311 
Height (cm) 168.5 ± 1.1 166.1 ± 1.7 -1.9 to 6.6 0.275 
Mass (kg) 58.0 ± 0.9 71.8 ± 1.5 -17.6 to -9.9 <0.001 
BMI 20.3 ± 0.2 25.7 ± 0.4 -6.4 to -4.4 <0.001 
Systolic BP (mm Hg) 118 ± 3  123 ± 2 -3.1 to 13.8 0.211 
Diastolic BP (mm Hg) 70.9 ± 1.9 63.8 ± 3.1 -0.4 to 14.7 0.065 
HOMA-IR 1.7 ± 0.2 1.9 ± 0.3 -0.8 to 0.4 0.525 
TC:HDL-c Ratio 3.2 ± 0.2 3.4 ± 0.3 -1.1 to 0.5 0.523 
C-reactive protein  (mg/L) 2.6 ± 0.4 3.5 ± 0.6 -2.5 to 0.7 0.270 
Cardiorespiratory fitness (shuttles) 76.1 ± 2.7 71.3 ± 4.5 -6.3 to 16.1 0.384 
Cardiometabolic risk* 1.3 ± 0.3 1.6 ± 0.6 -1.7 to 1.2  0.733 
Cardiometabolic risk** 2.1 ± 0.4 2.2 ± 0.6 -1.5 to 1.4 0.949 
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Table 3 – Comparison of anthropometric, body composition and cardiometabolic risk variables between normal weight and obese/overweight participants 
with and without the HTWP. 
 
Values are presented as mean ± (SE). BMI = Body mass index; HOMA-IR = homeostasis model assessment for Insulin Resistance; TC:HDL-c Ratio = Total 
cholesterol to high-density lipoprotein cholesterol ratio.  
* Cardiometabolic risk score excluding cardiorespiratory fitness 
** Cardiometabolic risk score including cardiorespiratory fitness 
 
 
 Normal Weight 
 
Overweight / Obese  
 
Variable Non HTWP (n = 
170) 
HTWP (n = 55) 95% CI for 
difference 
P value Non HTWP (n = 
134) 
HTWP (n = 28) 95% CI for 
difference 
P value 
Age (yrs) 13.0  ± 0.2 15.6 ± 0.3 -3.1 to -2.0 <0.001 14.1 ± 0.2 15.4 ± 0.3 -2.1 to -0.5 0.003 
Height (cm) 160.4 ± 0.9 168.5 ± 1.1 -2.1 to 5.1 0.399 161.0 ± 1.0 166.1 ± 1.7 -5.9 to 2.1 0.353 
Mass (kg) 50.4 ± 0.8 58.0 ± 0.9 -2.1 to 4.0 0.534 66.1 ± 1.0 71.8 ± 1.5 -7.4 to 3.2 0.431 
BMI 19.2 ± 0.1 20.3 ± 0.2 -0.8 to 0.5 0.637 25.3 ± 0.3 25.7 ± 0.4 -1.8 to 1.4 0.797 
Systolic BP (mm Hg) 116 ± 1 118 ± 3 -6.6 to 2.9 0.459 120 ± 1 123 ± 2 -7.3 to 6.7 0.934 
Diastolic BP (mm Hg) 67 ± 1 70.9 ± 1.9 -4.7 to 3.6 0.796 72 ± 1 63.8 ± 3.1 -1.4 to 11.4 0.127 
HOMA-IR 1.4 ± 0.1 1.7 ± 0.2 -0.6 to 0.2 0.305 1.6 ± 0.1 1.9 ± 0.3 -0.9 to 0.2 0.261 
TC:HDL-c Ratio 2.6 ± 0.1 3.2 ± 0.2 -1.2 to -0.4 <0.001 3.3 ± 0.1 3.4 ± 0.3 -1.1 to 0.3 0.297 
C-reactive protein  (mg/L) 1.6 ± 0.3 2.6 ± 0.4 -2.1 to 0.7 0.032 2.6 ± 0.5 3.5 ± 0.6 -3.3 to 1.7 0.014 
Cardiorespiratory fitness 
(shuttles) 
72.2 ± 1.8 76.1 ± 2.7 -4.8 to 6.5 0.292 73.8 ± 4.2  71.3 ± 4.5 -4.7 to 5.2 0.116 
Cardiometabolic risk* -0.7 ± 0.2  1.3 ± 0.3 -2.2 to -0.6 0.001 0.9 ± 0.2 1.6 ± 0.6 -2.2 to 0.2 <0.001 
Cardiometabolic risk** -0.5 ± 0.2 2.1 ± 0.4 -2.2 to -0.5 0.002 0.8 ± 0.2 2.2 ± 0.6 -2.8 to -0.2 <0.001 
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Supplementary Table 1. Multivariate-adjusted OR (and 95% CI) for cardiometabolic risk indicators across WC categories (healthy WC = reference group), 
BMI categories (non-overweight = reference group) and HTWP (non-HTWP = reference group) 
 HTWP† Waist Circumference  † BMI †  
Independent variable  
(Top tertile vs. rest) 
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value 
TC:HDL-c Ratio 0.86 (0.52 - 1.43) 0.560 0.45 (0.25 - 0.82) 0.009 0.73 (0.40 - 1.32) 0.294 
HOMA 1.17 (0.63 - 2.16) 0.616 0.95 (0.47 - 1.93) 0.108 1.02 (0.22 - 4.82) 0.982 
Systolic BP (mm Hg) 0.49 (0.31 - 0.78) 0.003 0.85 (0.47 - 1.55) 0.596 1.04 (0.40 - 2.73) 0.938 
Diastolic BP (mm Hg) 1.16 (1.07 - 1.25) 0.015 0.89 (0.51 - 1.54) 0.670 0.51 (0.16 - 1.63) 0.254 
Cardiorespiratory fitness (shuttles) ǂ 4.89 (2.59 - 9.19) <0.001 1.43 (0.71 - 2.85) 0.316 0.13 (0.04 - 0.43) 0.001 
C-reactive protein  (mg/L)* 0.48 (0.29 - 0.78) 0.003 0.85 (0.42 - 1.72) 0.002 0.58 (0.24 - 1.41) 0.226 
Cardiometabolic risk* 0.28 (0.17 - 0.46) <0.001 0.93 (0.35 - 2.49) <0.001 0.26 (0.07 - 1.05) 0.058 
Cardiometabolic risk** 0.44 (0.26 - 0.75) 0.002 0.53 (0.18 - 1.54) <0.001 0.72 (0.19 - 2.67) 0.617 
For all models: Tertiles were age, sex, SES and study location adjusted. BMI = Body mass index; HOMA-IR = homeostasis model assessment for Insulin 
Resistance; TC:HDL-c Ratio = Total cholesterol to high-density lipoprotein cholesterol ratio. 
† The HTWP was defined according to thresholds previously applied (3) with triglyceride concentrations ≥1.24 mmol/L taken as elevated. A high waist 
circumference measurement was defined as ≥ 90th percentile for age and sex as previously described (22) whilst for participants aged ≥ 17 years, high WC 
in males and females was defined as ≥ 94 and 80 cm in accordance with the International Diabetes Federation (21). BMI was calculated and used to classify 
participants as obese/overweight or a healthy weight using recommended international age and gender-specific BMI cut-off values (23). 
ǂ Bottom tertile vs. rest was used. 
* Cardiometabolic risk score excluding cardiorespiratory fitness. 
















Relative contribution of variables presented in decreasing order of magnitude. BMI = Body mass index; HOMA-IR = homeostasis model assessment for 
Insulin Resistance; TC:HDL-c Ratio = Total cholesterol to high-density lipoprotein cholesterol ratio. 
† The HTWP was defined according to thresholds previously applied (3) with triglyceride concentrations ≥1.24 mmol/L taken as elevated. A high waist 
circumference measurement was defined as ≥ 90th percentile for age and sex as previously described (22) whilst for participants aged ≥ 17 years, high WC 
in males and females was defined as ≥ 94 and 80 cm in accordance with the International Diabetes Federation (21).  
ǂ BMI was calculated and used to classify participants as obese/overweight, or a healthy weight using recommended international age and gender-specific 
BMI cut-off values (23).  
* Cardiometabolic risk score excluding cardiorespiratory fitness. ** Cardiometabolic risk score including cardiorespiratory fitness. 
≠ P < 0.05 
HTWP† 
Healthy Weightǂ Overweight / Obeseǂ 
Variable Standardized discriminant 
function coefficient 
Variable Standardized discriminant 
function coefficient 
Cardiometabolic risk** -0.759≠ Cardiometabolic risk** 0.745≠ 
Cardiorespiratory fitness (Shuttles) 0.489≠ Cardiometabolic risk* 0.540≠ 
Cardiometabolic risk* -0.417≠ C-reactive protein  (mg/L) 0.339≠ 
Age (yrs) -0.410≠ Age 0.323≠ 
C-reactive protein  (mg/L) -0.406≠ Cardiorespiratory fitness (Shuttles) -0.322≠ 
Height (cm) -0.306 HOMA 0.256 
TC:HDL-c Ratio 0.287 Mass (kg) -0.220 
HOMA 0.226 Height (cm) -0.211 
Diastolic BP (mm Hg) -0.226 Systolic BP (mm Hg) 0.137 
Systolic BP (mm Hg) -0.138 Diastolic BP (mm Hg) -0.089 
Mass (kg) 0.034 TC:HDL-c Ratio 0.076 
